• 

  Sebi chief Madhabi Puri Buch dismisses conflict of interest allegations as false and defamatory

  Business | September 13, 2024 15:45 IST

  SEBI Chairperson Madhabi Puri Buch and her husband, Dhaval Buch, have dismissed conflict of interest allegations made by the Congress party as "false and defamatory." In a joint statement, they clarified that Dhaval's consulting roles were merit-based and predated her SEBI tenure.

• 

  Made in India Sputnik V to be available during September- October: Dr Reddy's

  India | July 27, 2021 17:49 IST

  Dr Reddy's, which has tied up with Russian Direct Investment Fund for Sputnik V in India, soft-launched the vaccine in India in May 2021 after receiving Emergency Use Authorization (EUA) in April 2021.

• 

  Sensex tanks 587 points; HDFC Bank slumps over 3 per cent

  July 19, 2021 17:13 IST

  Equity benchmark Sensex tanked 587 points on Monday, tracking heavy losses in HDFC twins, Reliance Industries, and Axis Bank amid a weak trend in global markets.

• 

  Sputnik V soft launched in over 50 cities in India: Dr Reddy's Laboratories

  India | July 13, 2021 10:27 IST

  Dr Reddys Laboratories Ltd, which soft-launched Russia's COVID-19 vaccine, Sputnik V on May 14 has expanded the pilot project to over 50 other cities and towns in the country.

• 

  Dr Reddy's posts Q4 profit of Rs 554 crore, revenues at Rs 4,728 crore

  Business | May 14, 2021 14:27 IST

  Net sales however rose to Rs 4,608 crore in the quarter under review as compared with Rs 4,336.1 crore in the fourth quarter of 2019-20, Dr Reddy's Laboratories said in a regulatory filing.

• 

  SEC to discuss Dr Reddy's application for emergency use of Sputnik V vaccine

  India | February 24, 2021 12:47 IST

  The Central Drugs Standard Control Organisation's (CDSCO) Subject Expert Committee (SEC) is going to meet on Wednesday afternoon to discuss Dr Reddy's Laboratories application seeking emergency use approval (EUA) for SputnikV, a Russian Vaccine.

• 

  Dr Reddy's begins process to obtain emergency use authorisation for Sputnik V

  Business | February 19, 2021 19:14 IST

  As part of the review process, the drug major will present the safety profile of phase 2 study, and interim data of phase 3 trial, which is expected to be complete by February 21, 2021, Dr Reddy's said in a statement.

• 

  Dr Reddy's eyes to launch Sputnik V vaccine for COVID-19 under EUA in March

  India | January 29, 2021 20:52 IST

  The ongoing trial was expected to be completed by February after which it would approach the Drug Controller General of India (DCGI) for EUA and based on its approval the vaccine could be launched in March, DRL's Chief Executive Officer of APIs and Pharmaceutical Services Deepak Sapra said.

• 

  Dr Reddy's partners with BIRAC for COVID-19 vaccine Sputnik V clinical trials in India

  Business | October 29, 2020 12:13 IST

  Dr Reddy's Laboratories Ltd on Thursday announced its partnership with Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT), for advisory support on clinical trials of Sputnik V vaccine in India.

• 

  Dr. Reddy's partners with Russia for clinical trial of Sputnik V in India

  India | September 16, 2020 15:24 IST

  Dr. Reddy's Laboratories has signed a deal with the Russian Direct Investment Fund to conduct a clinical trial and distribution of coronavirus vaccine Sputnik V in India. According to the agreement, Russia's sovereign wealth fund will supply 100 million doses of the COVID-19 vaccine to India. 

• 

  Dr Reddy's faces class action suit in US court

  August 28, 2017 18:23 IST

  The lawsuit alleges the company made materially false or misleading statements or omissions in connection with its corporate quality system and specifically in connection with a warning letter from the US FDA, DRL said in a filing

Advertisement
• 

  Dr Reddy's Q2 net down 17% at Rs 574.1 cr

  October 29, 2014 19:48 IST

  New Delhi: Pharmaceuticals major Dr Reddy's Laboratories Wednesday reported 16.82 percent decline in its consolidated net profit at Rs 574.1 crore for the second quarter ended September 30, 2014 on account of higher expenses.The company

• 

  Dr Reddy's Apr-Jun Net up 7% at Rs 361 cr

  July 30, 2013 18:44 IST

  New Delhi, July 30: Drug maker Dr Reddy's Laboratories on Tuesday said its net profit rose by over 7% to Rs 361 crore for the quarter ended June 30, primarily driven by North American revenues. The

• 

  Dr Reddy's sued for 'infringement' of thyroid injection patent

  June 19, 2013 13:06 IST

  Hyderabad, June 19: US-based drug maker AbbVie Inc, the spun-off entity of Abbott, has dragged Dr Reddy's Lab to court for allegedly infringing the former's patented drug Zemplar on six counts concerning three patents."DRL committed

• 

  Dr Reddys Q4 net up 67% at Rs 571 crore

  May 14, 2013 15:49 IST

  New Delhi, May 14: Drug firm Dr Reddy's Laboratories has reported a 66.58 per cent rise in its net profit to Rs 570.89 crore for the quarter ended March 31, 2013 mainly on account of